| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | BMS-754807 | FIMM | pan-cancer | AAC | -0.1 | 0.4 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.4 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | isonicotinohydroxamic acid | CTRPv2 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |